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ABSTRACT
Granulocyte colony-stimulating factor (G-CSF) has been reported to exacerbate vaso-occlusive crises in sickle
cell disease. It has been recommended to avoid its use for stem cell mobilization in this population, yet autolo-
gous transplant is the standard of care and at times a life-saving treatment for patients with various hematologic
malignancies such as relapsed aggressive lymphoma or multiple myeloma. We report 5 cases of patients with
sickle cell disease and related hemoglobinopathies who underwent granulocyte-colony stimulating factor
(G-CSF)-mobilization of peripheral blood stem cells (PBSC). Three of them developed manageable vaso-
occlusive pain symptoms requiring parenteral narcotics alone. The 2 others had no complications. These cases
demonstrate that stem cell mobilization using G-CSF, although complicated and not without risk, is feasible in
patients with sickle cell syndromes.
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The feasibility of stem cell mobilization in sickle
cell disease (SCD) has been questioned, as granulocyte
colony-stimulating factor (G-CSF) can exacerbate
vaso-occlusive crises (VOC) [1-3]. We report our ex-
perience of 5 adults in total: 4 with hemoglobin SS
(HbSS), and 1 with hemoglobin SC (HbSC) disease
who underwent G-CSF mobilization followed by pe-
ripheral blood stem cell (PBSC) collection either prior
to receiving an autologous stem cell transplant (auto-
SCT) for relapsed lymphoma or as back-up for
a planned allogeneic stem cell transplant (allo-SCT)
for severe SCD.
Patients
The clinical features of the 5 patients at presenta-
tion and during mobilization are shown in Table 1.
All patients participated in institutional review
board-approved studies, and consents to collect
mobilized PBSCs were obtained that explained the
risks of the procedure. Apheresis was performed ac-cording to standards for autologous [4] or normal
donor [5] collection. A brief description of each pa-
tient follows.
Patient 1
A 40-year-old woman with HbSS disease compli-
cated by frequent VOC and severe end-organ damage
including end-stage renal disease underwent back-up
autologous PBSC collection prior to planned allo-
SCT.
She received G-CSF 5 mg/kg twice daily for 3 con-
secutive days. On day 3 (d3), outpatient leukapheresis
was performed with a peak WBC count of 41  109/L
and peripheral blood (PB) CD341 count of 25.3/mL.
During the procedure, she became hypertensive and
developed generalized bone pain requiring a 24-hour
hospitalization. The following day, her hypertension
and symptoms resolved and leukapheresis was success-
ful with WBC and PB CD341 counts of 34  109/L
and 22.8/mL, respectively, resulting in a combined
2-day yield of 3.29  106/kg CD341 cells.719
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4. Pulmonary embolism
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A 56-year-old woman with HbSC disease compli-
cated by frequent VOC, recurrent pulmonary emboli,
cerebral infarcts, avascular necrosis of bilateral hips
and shoulders, and proliferative retinitis underwent
back-up autologous PBSC collection prior to planned
allo-SCT.
HbS and HbC levels were 46% and 47%, respec-
tively. She received G-CSF 5 mg/kg twice daily for 3
consecutive days. The WBC count was 53  109/L
and PB CD341 count 16.38/mL on the first day of col-
lection, with 1.63  106/kg CD341 cells in total col-
lected over 2 days. No complications related to
mobilization occurred.
Patient 3
An 18-year-old woman with HbSS disease compli-
cated by numerous VOC, recurrent episodes of pneu-
monia, acute chest syndrome (ACS), and frequent
transfusions underwent back-up autologous PBSC
collection prior to planned allo-SCT.
HbS level was approximately 75% prior to receiv-
ing G-CSF 5 mg/kg twice daily for 3 days followed by 2
days of outpatient leukapheresis. On collection day 1,
the WBC count was 44.1  109/L and PB CD341
count 21.52/mL, which peaked at 23.54/mL on d2. A
2-day collection yielded 2.29  106/kg CD341 cells.
No complications related to mobilization occurred.
She subsequently underwent allo-SCT but re-
jected the graft. On d30, the previously collected au-
tologous stem cells were infused because of
persistent pancytopenia and graft failure. Autologous
recovery occurred 10 days after infusion of back-up
stem cells.
Patient 4
A 23-year-old woman with HbSS disease and fre-
quent VOC complicated by episodes of ACS and tran-
sient ischemic attacks underwent back-up autologous
PBSC collection prior to planned allo-SCT.
G-CSF 5 mg/kg twice daily was started although
mild vaso-occlusive pain developed requiring hospital-
ization. HbS level was 25%. Subsequently, G-CSFwas
briefly held for bifrontal headaches attributed to leu-
kocytosis with a WBC count of 60  109/L. Harvest
was unsuccessful as the PB CD341 count was negligi-
ble. Her headaches resolved and G-CSF was restarted
at 5 mg/kg daily. Six days later, leukapheresis was per-
formedwith a peakWBC count of 105 109/L and PB
CD341 count of 68.25/mL. Two days of collection
yielded a total of 7.01  106/kg CD341 cells.
Patient 5
A 30-year-old woman with HbSS disease and re-
current Hodgkin lymphoma (HL) underwent chemo-therapy-based stem cell mobilization prior to planned
auto-SCT.
She had mild vaso-occlusive pain responsive to
narcotics prior to beginning chemotherapy. She re-
ceived ifosfamide 3330 mg/m2 by continuous infusion
for 3 days, etoposide 150 mg/m2 every 12 hours for
3 days, and 5 mg/kg of G-CSF daily starting d5, in-
creased to twice daily on d11 and d12. Baseline hemo-
globin ranged between 9 g/dL and 10 g/dL.
Transfusions were given to maintain HbS\30% prior
to leukapheresis, and reduced the percentage to
14.4%. On d8, 3 days after initiating G-CSF, she de-
veloped back and extremity pain, which improved
with narcotics. On d13, PBSCs were collected when
the WBC count recovered to 10  109/L and a peak
PB CD341 count was 307/mL. A 1-day collection
yielded 28.6  106/kg CD341 cells. She subsequently
underwent auto-SCT, and remains in complete remis-
sion 1 year posttransplant.
Results and Discussion
Leukocytosis, and in particular granulocytosis
with neutrophil activation, has been postulated to
play a key role in both steady-state and acute compli-
cations of SCD [6]. In 1 case report, an asymptomatic
donor with HbSC disease developed a fatal VOC dur-
ing G-CSF-mobilization with a peak WBC count of
71 109/L [1]. Another case report highlights a breast
cancer patient with asymptomatic sickle cell disease/
b1thalassaemia and HbS component of 57% who re-
ceived daily G-CSF during adjuvant chemotherapy
and developed acute multiorgan failure syndrome after
4 doses [2]. No leukocytosis was observed because of
recent chemotherapy administration. The authors
postulate that a threshold HbS level may predispose
to VOC and severe complications, acknowledging
the report by Kang et al. [7], which shows the safety
of administering G-CSF in sickle cell trait patients
with HbS levels of 35%-40%. Abboud et al. [3] con-
clude that G-CSF-mobilization is unsafe in this popu-
lation based on a report of a SCD patient who
developed ACS with marked leukocytosis on the
fourth day of G-CSF administration, which resolved
with hydroxyurea and G-CSF withdrawal.
By contrast, in our experience complications of
PBSC mobilization were transient, and occurred in
only 3 of 5 patients but without correlation to percent-
age of HbS. Two patients developing mild VOC with
pain alone had low HbS levels of 14% and 25%,
whereas patients with higher HbS levels had no com-
plications. The patient with the HbS level of 14%
was the only one who had received packed red blood
cell transfusions to lower the HbS percentage prior
to leukapheresis, while the remainder of the cohort re-
ceived no transfusions. Nevertheless, we caution
against performing G-CSF-based mobilization with
722 C. Rosenbaum et al.hemoglobin S levels .30% based on literature that
specifies a therapeutic goal of decreasing hemoglobin
S levels to\30% with red cell exchange transfusion
in the setting of VOC [8]. The peak WBC count dur-
ing mobilization should also be monitored closely and
values.80,000/mL should be avoided by early discon-
tinuation of G-CSF [1,9,10]. All patients had a marked
rise in their WBC counts at the time of collection ex-
cept for the patient with HL who was recovering from
mobilizing chemotherapy. Of the 3 patients develop-
ing symptoms, 1 had bone pain prior to receiving
G-CSF, and worsening pain during mobilization was
manageable with parenteral narcotics. Two others
developed mild bone pain and headaches, respectively,
which did not interfere with collection of adequate
stem cell yields. Others have reported similar results
with G-CSF mobilization in SCD patients with
relapsed lymphoma requiring auto-SCT. A recent
report demonstrates the safety and efficacy of
G-CSF-mobilization in a HbSC patient undergoing
auto-SCT for diffuse large B-cell lymphoma [11]. G-
CSF was administered twice daily in a split-dose
schedule to minimize leukocytosis, and hypophospha-
temia was avoided during mobilization. In another re-
port, an SCD patient undergoing autologous bone
marrow transplantation for diffuse large B-cell lym-
phoma received G-CSF following initial chemother-
apy administration and posttransplantation, similar
to our patient [12]. In both reports, a lowHbS percent-
age was maintained throughout the transplant with
strategies of exchange transfusion and hypertransfu-
sion, respectively, which effectively lowered HbS
levels to 6% and 0%. The authors in the latter report
comment that hypertransfusion may prevent G-CSF-
induced complications in SCD.
As the average life expectancy of patients with SCD
increases, patients with concomitant hematologic ma-
lignancies are encountered more frequently, and some
need an auto-SCT. The recommendation to avoid
stem cell mobilization takes into account only the risks
but not the benefits of auto-SCT, nor the risks of alter-
native treatment options. Although complications
were frequent after G-CSF-mobilization, they were
transient and manageable. Methods such as hydroxy-
urea withdrawal have not proved to be effective for
stem cell mobilization [13]. The novel mobilizing
agent, AMD3100, is investigational and associated
with its own side effect profile, has not yet been studied
in this patient population, and has demonstrated high-
est efficacy when used in combination with G-CSF
[14]. Phase II studies of AMD3100 in normal partici-
pants to date report higher stem cell yields with the
addition of AMD3100 to G-CSF compared to
AMD3100 given as a single agent [15-17]. An alterna-
tive option to procure stem cells would be to harvest
bone marrow, but this usually requires general anes-
thesia, which entails considerable risks in patientswith SCD [18]. Allo-SCT is curative for both SCD
and hematologic malignancies, but has a high rate of
fatal complications such as graft rejection and graft
failure [19,21]. Furthermore, the likelihood of identi-
fying a related or matched unrelated donor is low
[22,23].
Our case series demonstrates that G-CSF mobili-
zation can be performed with a tolerable risk profile
and manageable VOC symptoms, and that adequate
stem cell yields are achievable in patients with sickle
cell syndromes in need of a hematopoietic SCT. A bet-
ter understanding of the complex relationship between
HbS levels, leukocytosis, and the rate of WBC count
rise in provoking VOC is necessary for further improv-
ing the tolerability of G-CSF mobilization in this pa-
tient population.
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